Crinetics' Acromegaly Drug Shows Promise in Phase 3 Trial, Faces Tough Competition
TL;DR
Crinetics Pharmaceuticals' experimental drug for acromegaly, a rare hormonal disorder, has shown success in a late-stage trial, with 25 out of 30 patients given the drug achieving normal growth-factor levels compared to just 1 out of 28 participants who took the placebo. The company plans to file for FDA approval pending positive results from a second Phase 3 trial. However, if approved, Crinetics would face tough competition from existing blockbuster therapies sold by pharmaceutical giants in the crowded market.
Topics:businesshealth#acromegaly#crinetics-pharmaceuticals#drug-trial#fda-approval#growth-hormone#health
- Crinetics acromegaly drug succeeds in late-stage trial but would face stiff competition if approved STAT
- Crinetics (NASDAQ:CRNX) Jumps 37% on Positive Phase 3 Results - TipRanks.com TipRanks
- Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly Yahoo Finance
- Crinetics stock climbs as lead asset succeeds in acromegaly Seeking Alpha
- Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on STAT